| Net Loss per Share |
2. Net Loss per Share
Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding, less Restricted Stock Awards (“RSAs”) subject to forfeiture. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding, less RSAs subject to forfeiture, plus all additional common shares that would have been outstanding, assuming dilutive potential common shares had been issued for other dilutive securities.
For the three and six months ended June 30, 2015 and 2014, diluted and basic net loss per common share were identical since potential common shares were excluded from the calculation, as their effect was anti-dilutive.
Anti-Dilutive Securities
The following common equivalent shares were not included in the computation of diluted net loss per share because their effect was anti-dilutive:
|
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
|
|
(In thousands)
|
|
2015(1)
|
|
2014
|
|
2015(2)
|
|
2014
|
|
|
Outstanding options and awards granted under equity incentive plan and employee stock purchase plan
|
|
5,440
|
|
6,136
|
|
5,653
|
|
5,942
|
|
|
Unvested RSAs
|
|
1,738
|
|
2,039
|
|
1,863
|
|
2,150
|
|
|
Shares issuable upon conversion of convertible subordinated notes
|
|
12,678
|
|
13,486
|
|
12,678
|
|
13,486
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
19,856
|
|
21,661
|
|
20,194
|
|
21,578
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
| |
Includes 4.2 million options, 0.4 million restricted stock units, and 1.1 million unvested RSAs retained by former employees who were transferred to Theravance Biopharma in connection with the Spin-Off during the three months ended June 30, 2015. Subsequent to the Spin-Off, stock-based compensation expense associated with the awards held by Theravance Biopharma employees granted prior to the Spin-Off is recognized by Theravance Biopharma. |
|
(2)
| |
Includes 4.4 million options, 0.5 million restricted stock units, and 1.2 million unvested RSAs retained by former employees who were transferred to Theravance Biopharma in connection with the Spin-Off during the six months ended June 30, 2015. Subsequent to the Spin-Off, stock-based compensation expense associated with the awards held by Theravance Biopharma employees granted prior to the Spin-Off is recognized by Theravance Biopharma. |
|